These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 26626120)

  • 41. Management of acute hepatitis B and reactivation of hepatitis B.
    Jindal A; Kumar M; Sarin SK
    Liver Int; 2013 Feb; 33 Suppl 1():164-75. PubMed ID: 23286861
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Changes in the balance between Treg and Th17 cells in patients with chronic hepatitis B.
    Su ZJ; Yu XP; Guo RY; Ming DS; Huang LY; Su ML; Deng Y; Lin ZZ
    Diagn Microbiol Infect Dis; 2013 Aug; 76(4):437-44. PubMed ID: 23747030
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Therapy of hepatitis B].
    Thimme R; Blum HE
    Praxis (Bern 1994); 2006 Sep; 95(36):1383-8. PubMed ID: 16989181
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Natural YMDD-motif mutants affect clinical course of lamivudine in chronic hepatitis B.
    Tan YW; Ye Y; Ge GH; Zhao W; Gan JH; Zhao Y; Niu ZL; Zhang DJ; Chen L; Yu XJ; Yang LJ
    World J Gastroenterol; 2015 Feb; 21(7):2089-95. PubMed ID: 25717242
    [TBL] [Abstract][Full Text] [Related]  

  • 45. "Receptor-ligand" based new strategy for treatment of patients with chronic hepatitis B.
    Meyer SD; Yap SH
    Acta Gastroenterol Belg; 1998; 61(2):234. PubMed ID: 9658617
    [No Abstract]   [Full Text] [Related]  

  • 46. Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B.
    Liaw YF
    J Gastroenterol Hepatol; 2004 Dec; 19 Suppl 6():S73-5. PubMed ID: 15546254
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations.
    Yuen MF; Ahn SH; Chen DS; Chen PJ; Dusheiko GM; Hou JL; Maddrey WC; Mizokami M; Seto WK; Zoulim F; Lai CL
    J Clin Gastroenterol; 2016 Apr; 50(4):286-94. PubMed ID: 26840752
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chronic HBV without e antigen: using HBV DNA to guide management.
    Tran T; Martin P
    Am J Gastroenterol; 2003 Oct; 98(10):2115-7. PubMed ID: 14572554
    [No Abstract]   [Full Text] [Related]  

  • 49. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine.
    Vandepapelière P; Lau GK; Leroux-Roels G; Horsmans Y; Gane E; Tawandee T; Merican MI; Win KM; Trepo C; Cooksley G; Wettendorff M; Ferrari C;
    Vaccine; 2007 Dec; 25(51):8585-97. PubMed ID: 18031872
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunomodulation therapy in children with chronic hepatitis B.
    Karaoglan M; Demirci F; Coskun Y; Karaoglan I; Bayraktaroglu Z; Okan V; Karsligil T
    J Natl Med Assoc; 2006 Feb; 98(2):143-7. PubMed ID: 16708498
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Emerging pipeline drugs for hepatitis B infection.
    Cox N; Tillmann H
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):713-29. PubMed ID: 22195605
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Hepatitis B virus e antigen plays an important role in the treatment for chronic hepatitis B].
    Kanda T; Nakamoto S; Sasaki R; Wu S
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():531-4. PubMed ID: 26845991
    [No Abstract]   [Full Text] [Related]  

  • 53. HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa?
    Vlachogiannakos J; Papatheodoridis GV
    Liver Int; 2014 Feb; 34 Suppl 1():127-32. PubMed ID: 24373089
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New therapeutic agents for chronic hepatitis B.
    Brahmania M; Feld J; Arif A; Janssen HL
    Lancet Infect Dis; 2016 Feb; 16(2):e10-21. PubMed ID: 26795693
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus.
    Wang FS; Zhang Z
    Expert Rev Gastroenterol Hepatol; 2009 Oct; 3(5):499-512. PubMed ID: 19817672
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of peginterferon alpha-2a (40KD) in HBeAg-positive chronic hepatitis B patients.
    Caruntu FA; Streinu-Cercel A; Gheorghe LS; Grigorescu M; Sporea I; Stanciu C; Andronescu D; Voinea F; Diculescu M; Oproiu A; Voiosu R
    J Gastrointestin Liver Dis; 2009 Dec; 18(4):425-31. PubMed ID: 20076814
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chronic hepatitis B: a treatment update.
    Wong VW; Chan HL
    Semin Liver Dis; 2013 May; 33(2):122-9. PubMed ID: 23749668
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Latest developments in the treatment of hepatitis B.
    Dandri M; Petersen J
    Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hepatitis B re-activation with rituximab therapy: treat the patient not the disease.
    Zachou K; Dalekos GN
    Liver Int; 2011 Mar; 31(3):277-9. PubMed ID: 21281426
    [No Abstract]   [Full Text] [Related]  

  • 60. Targeting innate immunity: a new step in the development of combination therapy for chronic hepatitis B.
    Zoulim F; Luangsay S; Durantel D
    Gastroenterology; 2013 Jun; 144(7):1342-4. PubMed ID: 23710602
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.